KPRX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
KPRX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Kiora Pharmaceuticals has the Financial Strength Rank of 9. It shows strong financial strength and is unlikely to fall into distressed situations.
Good Sign:
Kiora Pharmaceuticals Inc shows strong financial strength.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.GuruFocus does not calculate Kiora Pharmaceuticals's interest coverage with the available data. Kiora Pharmaceuticals's debt to revenue ratio for the quarter that ended in Mar. 2024 was 0.00. As of today, Kiora Pharmaceuticals's Altman Z-Score is -1.76.
For the Biotechnology subindustry, Kiora Pharmaceuticals's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Kiora Pharmaceuticals's Financial Strength distribution charts can be found below:
* The bar in red indicates where Kiora Pharmaceuticals's Financial Strength falls into.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Kiora Pharmaceuticals's Interest Expense for the months ended in Mar. 2024 was $0.00 Mil. Its Operating Income for the months ended in Mar. 2024 was $13.21 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.05 Mil.
Kiora Pharmaceuticals's Interest Coverage for the quarter that ended in Mar. 2024 is
GuruFocus does not calculate Kiora Pharmaceuticals's interest coverage with the available data. |
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. Kiora Pharmaceuticals Inc has enough cash to cover all of its debt. Its financial situation is stable.
2. Debt to revenue ratio. The lower, the better.
Kiora Pharmaceuticals's Debt to Revenue Ratio for the quarter that ended in Mar. 2024 is
Debt to Revenue Ratio | = | Total Debt (Q: Mar. 2024 ) | / | Revenue | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | Revenue | |
= | (0.048 | + | 0.046) | / | 64 | |
= | 0.00 |
3. Altman Z-Score.
Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
The zones of discrimination were as such:
When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.
Kiora Pharmaceuticals has a Z-score of -1.76, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.
Warning Sign:
Altman Z-score of -1.76 is in distress zone. This implies bankruptcy possibility in the next two years.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kiora Pharmaceuticals (NAS:KPRX) Financial Strength Explanation
The maximum rank is 10. Companies with rank 7 or higher will be unlikely to fall into distressed situations. Companies with rank of 3 or less are likely in financial distress.
Kiora Pharmaceuticals has the Financial Strength Rank of 9. It shows strong financial strength and is unlikely to fall into distressed situations.
Thank you for viewing the detailed overview of Kiora Pharmaceuticals's Financial Strength provided by GuruFocus.com. Please click on the following links to see related term pages.
Carmine N. Stengone | director | 10578 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO CA 92121 |
Melissa Tosca | officer: EVP of Finance | C/O KIORA PHARMACEUTICALS, INC., 1371 EAST 2100 SOUTH, SUITE 200, SALT LAKE CITY UT 84105 |
Susan L. Drexler | officer: Interim CFO | 630 W. GERMANTOWN PIKE, SUITE 215, PLYMOUTH MEETING PA 19462 |
Erin Parsons | director | 97 WILLISTON RD, BROOKLINE MA 02445 |
David Hollander | director | C/O AERIE PHARMACEUTICALS, INC., 4301 EMPEROR BLVD., SUITE 400, DURHAM NC 27703 |
Brian M. Strem | director, officer: President and CEO | C/O EYEGATE PHARMACEUTICALS INC., 271 WAVERLY OAKS RD., STE 108, WALTHAM MA 02452 |
Eric Joseph Daniels | officer: Chief Development Officer | C/O EYEGATE PHARMACEUTICALS INC., 271 WAVERLY OAKS RD., STE 108, WALTHAM MA 02452 |
Armistice Capital Master Fund Ltd. | director, 10 percent owner | C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022 |
Steven Boyd | director, 10 percent owner | 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022 |
Armistice Capital, Llc | director, 10 percent owner | 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022 |
Aron Shapiro | director | C/O EYEGATE PHARMACEUTICALS INC., 271 WAVERLY OAKS RD., STE 108, WALTHAM MA 02452 |
Kenneth L Gayron | director | 75 NETWORK DRIVE, BURLINGTON MA 34212 |
Franz Obermayr | officer: Acting CEO | C/O EYEGATE PHARMACEUTICALS, INC., 271 WAVERLEY OAKS ROAD, SUITE 108, WALTHAM MA 02452 |
Bernard Malfroy-camine | director | C/O BURNS & LEVINSON LLP, 125 SUMMER STREET, BOSTON MA 02110 |
Thomas Hancock | director | C/O BURNS & LEVINSON LLP, 125 SUMMER STREET, BOSTON MA 02110 |
From GuruFocus
By Marketwired Marketwired • 07-26-2021
By ACCESSWIRE ACCESSWIRE • 08-07-2020
By Marketwired Marketwired • 09-08-2021
By Marketwired Marketwired • 08-12-2021
By Marketwired Marketwired • 09-09-2021
By Marketwired Marketwired • 08-10-2021
By [email protected] [email protected] • 06-01-2020
By Marketwired Marketwired • 12-21-2020
By Marketwired Marketwired • 01-06-2021
By Marketwired Marketwired • 05-12-2021
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.